Curis Provides Third Quarter 2026 Business Update
PR Newswire•12/11/2026•16:01 ET
1
Key Highlights
- ➤Q3 net loss $8.1 million, or $1.94 per share
- ➤TakeAim CLL enrolled 12 patients; initial data expected December 2026
- ➤TakeAim Lymphoma showed 86% ORR in BTKi-naïve patients
- ➤TakeAim Lymphoma showed 26% ORR in BTKi-experienced patients
- ➤October private placement proceeds extend cash runway into first quarter 2027
Expert Statements
James Dentzer, Chief Executive Officer of Curis
“We are encouraged by our progress in both the TakeAim CLL study and the TakeAim Lymphoma study”
James Dentzer, Chief Executive Officer of Curis
“The excitement among clinicians and patients reflects the clear unmet need in both CLL and PCNSL, where emavusertib has the potential to change the treatment landscape when combined with approved BTK inhibitors.”
Curis Provides Third Quarter 2026 Business Update PR Newswire
Management to host conference call and webcast today at 4:30 p.m. ET
Get started
Create a free account to read the full story.